Novel therapeutic strategies for impaired endothelium-dependent vascular relaxation

Bibliography

• FURCHGOTT RE CARVALHO MH, KHAN MT, MATSUNAGA K: Evidence for endothelium-dependent vasodilation of resistance vessels by acetylcholine. Blood Vessels (1987) 24:145–149.
   PubMedGoogle Scholar
• PALMER PM, FERRIGE AG, MONCADA S: Nitric oxide release accounts for the biological activity ofendothelium-derived relaxing factor. Nature (1987) 327:524–526.
   PubMed Web of Science ®Google Scholar
• TRIGGLE CR, DONG H, WALDRON GJ, COLE WC: Endothelium-derived hyperpolarizing factor(s): species and tissue heterogeneity. Clin. Exp. Pharmacol Physiol (1999) 26:176–179.
   PubMedGoogle Scholar
• TAYLOR HJ, CHAYTOR AT, EVANS WH, GRIFFITH TM: Inhibition of the gap junctional component of endothelium-dependent relaxations in rabbit iliac artery by 18-a glycyrrhetinic acid. Br. Pharmacol (1998) 125:1–3.
   PubMed Web of Science ®Google Scholar
• EDWARDS G, WESTON AH: EDHF-are there gaps in the pathway? " Physic] (2001) 531:299.
   Google Scholar
• BOLOTINA VM, NAJIBI S, PALACINO JJ, PAGANO PJ, COHEN RA: Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature (1994) 28:850–853.
   Google Scholar
• SUN CW, ALONSO-GALICIA M, TAHERI MR, FALCK JR, HARDER DR, ROMAN RJ: Nitric oxide-20- hydroxyeicosatetraenoic acid interaction in the regulation of K± channel activity and vascular tone in renal arterioles. Circ. Res. (1998) 83:1069–1079.
   PubMed Web of Science ®Google Scholar
• CROFT KD, MCGIFF JC, SANCHEZ-MENDOZA A, CARROLL MA: Angiotensin II releases 20-HETE from rat renal microvessels. Am. Physiol Renal. Physiol (2000) 279:F544–F551.
   Google Scholar
• KROETZ DL, HUSE LM, THURESSON A, GRILLO MP: Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney. Ma. Pharmacol (1997) 52:362–372.
   PubMedGoogle Scholar
• YE DZ, WANG DH: Function and regulation of endothelin-1 and its receptors in salt sensitive hypertension induced by sensory nerve degeneration. Hypertension (2002) 39:673–678.
   PubMedGoogle Scholar
• OYEKAN AO, YOUSEFF T, FULTON D, QUILLEYJ, MCGIFF JC: Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride.j Clin. Invest. (1999) 104:1131–1137.
   PubMedGoogle Scholar
• SAKAIRI Y, JACOBSON HR, NOLAND TD, BREYER MD: Luminal prostaglandin E receptors regulate salt and water transport in rabbit cortical collecting duct. Am. Physiol (1995) 269:F257–F265.
   Google Scholar
• CAMPBELL WB, GEBREMEDHIN D, PRATT PF, HARDER DR: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. (1996) 78:415–423.
   PubMed Web of Science ®Google Scholar
• ELIJOVICH F, LAFFER CL, AMADOR E, GAVRAS H, BRESNAHAN MR, SCHIFFRIN EL: Regulation of Plasma Endothelin by Salt in Salt-Sensitive. Circulation (2001) 103:263–268.
   PubMed Web of Science ®Google Scholar
• MAKITA K, TAKAHASHI K, KARARA A, JACOBSON HR, FALCK JR, CAPDEVILA JH: Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J. Clin. Invest (1994) 94:2414–2420.
   PubMed Web of Science ®Google Scholar
• ROMAN RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev (2002) 82:131–185.
   PubMedGoogle Scholar
• CHEN J, CAPDEVILAJH, ZELDIN DC, ROSENBERG RL: Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. MM. Pharmacol (1999) 55:288–295.
   PubMed Web of Science ®Google Scholar
• SHIMADA K, TAKAHASHI M, TANZAWA K: Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. Biol. Chem. (1994) 269:18275–18278.
   Web of Science ®Google Scholar
• NAVA E, LUSCHER TF: Endothelium-derived vasoactive factors in hypertension: nitric oxide and endothelin. I Hypertens. Sapp]. (1995) 13:S39–S48.
   Google Scholar
• KIOWSKI W: Endothelial function in humans. Studies of forearm resistance vessels. Hypertension (1991) 18:1184–1189.
   Web of Science ®Google Scholar
• BOULANGER CM: Secondary endothelial dysfunction: hypertension and heart failure. J. MM. Cell. Cardiol (1999) 31:39–49.
   PubMed Web of Science ®Google Scholar
• O'LEARY DH, POLAK JF, KRONMAL RA, MANOLIO TA, BURKE GL, WOLFSON SK Jr.: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N. Eng/. J. Med. (1999) 7:14–22.
   Google Scholar
• LUSCHER TF: 1993 Mack Forster Award Lecture. The endothelium as a target and mediator of cardiovascular disease. Eat J. Clin. Invest. (1993) 23:670–85.
   Google Scholar
• SHICHIRI M, HIRATA Y, ANDO K et al: Plasma endothelin levels in hypertension and chronic renal failure. Hypertension (1990) 15:493–496.
   PubMed Web of Science ®Google Scholar
• ERDOS EG, SKIDGEL RA: Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. (1989) 3:145–151.
   Google Scholar
• •This paper highlights early developments on neutral endopeptidase.
   Google Scholar
• TRIPPODO NC, ROBL JA, ASAAD MM, FOX M, PANCHAL BC, SCHAEFFER TR: Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am. J. Hypertens. (1998) 11:363–372.
   PubMed Web of Science ®Google Scholar
• ••These authors describe the potent effect ofomapatrilat as a dual inhibitor of NEP and ACE with long-lasting, oral antihypertensive property in low, normal and high renin models of hypertension. Omapatrilat was also suggested to be an effective, broad spectrum antihypertensive agent.
   Google Scholar
• CARMELIET P, NG YS, NUYENS D, THEILMEIER G et al.: Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. (1999) 5:495–502.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Angiogenesis and angiogenesis inhibition: an overview. EA'S (1997) 79:1–8.
   Google Scholar
• DVORAK H: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl. J. Med (1986) 315:1650–1659.
   Google Scholar
• MATTEI MG, BORG JP, ROSNET O, MARME D, BIRNBAUM D: Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively. Cenomics (1996) 32:168–169.
   Google Scholar
• MEYER M, CLAUSS M, LEPPLE-WIENHUES A et al.: A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. (1999) 18:63–374.
   Google Scholar
• KAIPAINEN A, KORHONEN J, MUSTONEN T et al.: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA (1995) 92:3566–3570.
   PubMed Web of Science ®Google Scholar
• GRIFFIOEN AW, MOLEMA G: Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev (2000) 52:237–68.
   PubMed Web of Science ®Google Scholar
• VALE PR, LOSORDO DW, SYMES JF, ISNER JM: Growth factors for therapeutic angiogenesis in cardiovascular diseases Rev Esp. Cardiol. (2001) 54:1210–1224.
   Google Scholar
• ••This paper reports that the administrationof recombinant proteins or genes encoding growth factors with angiogenic activity (VEGF of FGF) can paliate insufficient tissue perfusion secondary to obstruction of native arteries as an alternative therapy tompatients who fail to respond to conventional treatment (surgical or re-vascularisation).
   Google Scholar
• FERRARA N: Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol Cell. PhysioL (2001) 280:C1358–C1366.
   PubMed Web of Science ®Google Scholar
• ••This paper explains the dual role of VEGFas an important regulator of normal and abnormal angiogenesis. VEGF is reported to be essential for early development of the vasculature, female reproductive functions and endochondral bone formation, although it is also implanted in tumours and intraocular neovascular syndromes.
   Google Scholar
• FREEDMAN SB, ISNER JM: Therapeutic angiogenesis for coronary artery disease. Ann. Intern. Med. (2002) 136:54–71.
   PubMed Web of Science ®Google Scholar
• ISNER JM, BAUMGARTNER I, RAUH G et al.: Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J. Vasc. Surg. (1998) 28:964–973.
   PubMed Web of Science ®Google Scholar
• •An inipotant application of therapeutic angiogenesis with phVEGF165 gene transfer was proposed to treat patients with advanced Buerger's disease as an alternative to conventional medical or surgical methods.
   Google Scholar
• JONES MK, WANG H, PESKAR BM et al: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. (1999) 5:1418–1423.
   PubMed Web of Science ®Google Scholar
• FERRARA N: Molecular and biological properties of vascular endothelial growth factor. J. MM. Med. (1999) 77:527–543.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, REMUZZI G: Endothelin antagonists. Lancet (1999) 353:133–138.
   PubMed Web of Science ®Google Scholar
• •An important review with information ranging from the discovery to first clinical application of endothelin blockers.
   Google Scholar
• KRUM H, GOLDSMITH R, WILSHIRE-CLEMENT M, MILLER M, PACKER M: Role of endothelin in the exercise intolerance of chronic heart failure. Am. J. Cardiol (1995) 75:1282–1283.
   PubMed Web of Science ®Google Scholar
• KRUM H: New and emerging pharmacologic strategies in the management of chronic heart failure. Clin. Cardiol (2000) 23:724–730.
   PubMedGoogle Scholar
• NAVA E, NOLL G, LUSCHER TF: Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation (1995) 9:2310–2313.
   Google Scholar
• TORRE-AMIONE G, YOUNG JB, DURAND J et al.: Haemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation (2001) 103:973–980.
   PubMed Web of Science ®Google Scholar
• ••These authors suggest that tezosentan, anendothelin antagonist, can be safely administered to patients with moderate heart failure.
   Google Scholar
• BERGER R, STANEK B, HULSMANN M et al.: Effects of endothelin A receptor blockade on endothelial function in patients with chronic heart failure. Circulation (2001) 103:981–986.
   PubMed Web of Science ®Google Scholar
• LOUIS A, CLELAND JG, CRABBE Set al.: Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eut: J. Heart. Fail (2001) 3:381–387.
   Google Scholar
• ••This paper reports clinical trials on recentresearch relating to congestive heart failure.
   Google Scholar
• GIVERTZ MM, COLUCCI WS, LEJEMTEL TH et al.: Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation (2000) 101: 2922–2927.
   PubMed Web of Science ®Google Scholar
• ••This paper suggests that acute blockadewith a selective ETA receptor antagonist, sitaxsentan, resulted in selective pulmonary vasodilation associated with a reduction in plasma ET-1 in patients with moderate to severe heart failure receiving conventional therapy.
   Google Scholar
• SAKAI S, MIYAUCHI T, KOBAYASHI M, YAMAGUCHI I, GOTO K, SUGISHITA Y: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure Nature (1996) 384:353–355.
   Google Scholar
• FRANCIS G: Emerging data from heart failure trials: Clinical application. Can. J. Cardiol (1998) 14:27D–29D.
   Google Scholar
• THACKRAY SD, WITTE KK, KHAND A, DUNN A, CLARK AL, CLELAND JG: Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure. Eur: J. Heart Fail. (2001) 3:117–124.
   Google Scholar
• ••Summarises the recent research developments relative to the topic of heart failure.
   Google Scholar
• WADA A, TSUTAMOTOT, OHNISHI M, SAWAKI M, FUKAI D, MAEDA Y, KINOSHITA M: Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Circulation (1999) 99:570–577.
   PubMed Web of Science ®Google Scholar
• ••Endothelin-converting enzyme inhibitor isreported to reduce the secretion of neurohurnoral factors that are activated in congestive heart failure.
   Google Scholar
• KIRSTEN R, NELSON K, KIRSTEN D, HEINTZ B: Clinical pharmacokinetics of vasodilators. Part I. Clin. Pharmacokinet. (1998) 34:457–482.
   PubMed Web of Science ®Google Scholar
• HIRSCH AT, TALSNESS CE, SMITH AD, SCHUNKERT H, INGELFINGER JR, DZAU VI: Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation (1992) 86:1566–1574.
   PubMedGoogle Scholar
• •These investigators suggest that chronic treatment with captopril and enalapril elicts differential effects on tissue ACE activities as well as renal angiotensin regulation.
   Google Scholar
• SLEIGHT P: Angiotensin II and trials of cardiovascular outcomes. Am. j Cardin]. (2002) 89:11A–16A..
   Google Scholar
• ••Various dinaical trails of pharmacologicalagaents against cardio-circulatory disorders are discussed.
   Google Scholar
• OPARIL S: Are there meaningful differences in blood pressure control with current antihypertensive agents? Am. I Hypertens. (2002) 15:14S–21S.
   Google Scholar
• ••A comparision of the effects of angiotensin receptor blockers and ACEI was made.
   Google Scholar
• BOSCH J, YUSUF S, POGUE Jet al.: Use of ramipril in preventing stroke: double blind randomized trial. Br. Med. J. (2002) 324:699.
   Google Scholar
• ••The effectiveness of rarnipril in reducingthe incidence of stroke in high-risk patients is described.
   Google Scholar
• LONN E: Modifying the natural history of atherosclerosis: the SECURE trial. Int. Clin. Pract. (2001) 117:13–18.
   Google Scholar
• RAASCH W, DENDORFER A, BALL B, DOMINIAK P: The lipophilic properties of angiotensin I-converting enzyme inhibitors do not influence their diffusion through cultured endothelium. jpn. Pharmacol. (1999) 81:346–352.
   PubMedGoogle Scholar
• BACKLUND T, PALOJOKI E, GRONHOLM T et al.: Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo. Pharmacol Res. (2001) 44:411–418.
   PubMedGoogle Scholar
• RICHARDS AM, CROZIER IG, ESPINER EA, YANDLE TG, NICHOLLS MG: Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension. Hypertension (1993) 22:231–236.
   PubMedGoogle Scholar
• KAHN IC, PATEY M, DUBOIS-RANDE IL et al.: Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet (1990) 335:118–119.
   PubMed Web of Science ®Google Scholar
• PHAM I, GONZALEZ W, EL AMRANI Al et al.: Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. Pharmacol Exp. Titer. (1993) 265:1339–1347.
   Google Scholar
• CORTI R, BURNETT IC JR, ROULEAU IL, RUSCHITZKA F, LUSCHER TF: Vasopeptidase inhibitors: A new therapeutic concept in cardiovascular disease? Circulation (2001) 104:856–862.
   PubMedGoogle Scholar
• ••The authors outlined the therapeutic potentials of vasopeptide inhibitors.
   Google Scholar
• LUSCHER TF: Vascular protection: current possibilities and future perspectives. Int. J. Clin. Pract. Sapp]. (2001) 117:3–6.
   Google Scholar
• LAPOINTE N, ROULEAU IL: Cardio-protective effects of vasopeptidase inhibitors. Can. J. Cardiol (2001) 18:415–420.
   Google Scholar
• ••This review highlights the advantages ofvasopeptide inhibitors.
   Google Scholar
• ROULEAU JL, PFEFFER MA, STEWART DJ et al: Block AJ: comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 356:615–620.
   PubMed Web of Science ®Google Scholar
• NUSSBERGER J, CUGNO M, AMSTUTZ C, CICARDI M, PELLACANI A, AGOSTONI A: Plasma bradykinin in angio-oedema. Lancet (1998) 351:1693–1697.
   PubMed Web of Science ®Google Scholar
• BURNIER M, BRUNNER HR. Angiotensin II receptor antagonists. Lancet (2000) 355:637–645.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN SM, KAEMPFER CE, PROUD D, SCHWARTZ LB, IRANI A-MA, WINTROUB BU: Detection and partial characterization of a human mast cell carboxypeptidase. Immunol. (1987) 139:2724–2729.
   Google Scholar
• KOKKONEN JO, SAARINEN J, KOVANEN PT: Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation (1997) 95:1455–1463.
   Google Scholar
• BERRY C, TOUYZ R, DOMINICZAK AF, WEBB RC, JOHNS DG: Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am. I Physiol Heart Circ. Physiol (2001) 281:H2337–H2365.
   Google Scholar
• TIMMERMANS PB, WONG PC, CHIU AT et al.: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rey (1993) 45:205–251.
   PubMed Web of Science ®Google Scholar
• •The authors discussed the pharmacological concepts of angiotensin II receptors.
   Google Scholar
• ZUSMAN RM: Are there differences among angiotensin receptor blockers? Am. J. Hypertens. (1999) 12:231S–235S.
   Google Scholar
• ••This paper reports that randomised clinicaltrials of two angiotensin receptor blockers, irbesartan and losartan, are not equally effective in reducing blood pressure in pateints with hypertension. Futhermore, that combination of irbesartan with a diuretic was suggested to yield a more potent antihypertensive effect.
   Google Scholar
• WURZNER G, GERSTER JC, CHIOLERO A et al.: Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. Hypertens. (2001) 19:1855–1860.
   Google Scholar
• D'USCIO LV, SHAW S, BARTON M, LUSCHER TF: Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function. Hypertension (1998) 31:1305–1310.
   PubMed Web of Science ®Google Scholar
• LIMONE P, BOERI E, MOLINATTI GM: Role of the endothelium in the control of vascular motility: physiologic aspects and physiopathologic implications in cardiovascular diseases. Minerva Med. (1993) 84:499–505
   PubMedGoogle Scholar
• LUSCHER TF, VANHOUTTE PM, RAIJ L: Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension. (1987) 9:111193–111197.
   Google Scholar
• TSCHUDI MR, CRISCIONE L, NOVOSEL D, PFEIFFER K, LUSCHER TF: Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation (1994) 89:2212–2218.
   PubMed Web of Science ®Google Scholar
• DOHI Y, CRISCIONE L, PFEIFFER K,LUSCHER TF: Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused mesenteric resistance arteries. Cardiovasc. Pharmacol (1994) 24:372–379.
   PubMed Web of Science ®Google Scholar